A detailed history of Silver Oak Securities, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Silver Oak Securities, Inc holds 3,987 shares of ABBV stock, worth $717,660. This represents 0.09% of its overall portfolio holdings.

Number of Shares
3,987
Previous 3,466 15.03%
Holding current value
$717,660
Previous $594,000 32.49%
% of portfolio
0.09%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$163.84 - $199.33 $85,360 - $103,850
521 Added 15.03%
3,987 $787,000
Q2 2024

Jul 12, 2024

SELL
$154.79 - $180.76 $57,581 - $67,242
-372 Reduced 9.69%
3,466 $594,000
Q1 2024

May 10, 2024

BUY
$159.82 - $182.1 $80,709 - $91,960
505 Added 15.15%
3,838 $698,000
Q4 2023

Feb 05, 2024

SELL
$137.6 - $154.97 $139,113 - $156,674
-1,011 Reduced 23.27%
3,333 $516,000
Q3 2023

Nov 20, 2023

SELL
$133.59 - $154.65 $355,883 - $411,987
-2,664 Reduced 38.01%
4,344 $647,000
Q2 2023

Aug 02, 2023

BUY
$132.51 - $164.9 $57,376 - $71,401
433 Added 6.59%
7,008 $944,000
Q1 2023

May 05, 2023

SELL
$144.61 - $166.54 $97,033 - $111,748
-671 Reduced 9.26%
6,575 $1.05 Million
Q4 2022

Feb 02, 2023

BUY
$138.31 - $165.87 $35,269 - $42,296
255 Added 3.65%
7,246 $1.17 Million
Q3 2022

Oct 23, 2023

SELL
$134.21 - $153.93 $357,535 - $410,069
-2,664 Reduced 38.01%
4,344 $583,000
Q3 2022

Oct 20, 2022

BUY
$134.21 - $153.93 $16,373 - $18,779
122 Added 1.78%
6,991 $938,000
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $56,286 - $71,558
409 Added 6.33%
6,869 $1.02 Million
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $852,590 - $1.06 Million
6,460 New
6,460 $1.13 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Silver Oak Securities, Inc Portfolio

Follow Silver Oak Securities, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silver Oak Securities, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Silver Oak Securities, Inc with notifications on news.